SDC1 and Miyoshi myopathy: The efficacy of the GLVGLIFAV peptide was demonstrated by its ability to induce CD138-CTL anticancer activity against primary CD138+ cells isolated from HLA-A2+ MM patients and by the high level of intracellular IFNγ and cell proliferation in response to MM cell lines (195).